紫杉醇脂质体联合奈达铂治疗晚期非小细胞肺癌17例  

17 Cases of Advanced Non-small-cell Lung Cancer Treated with Paclitaxel Liposome plus Nedaplatin

作　　者：张金忠[1] 戈伟[1] 郑永法[1] 

机构地区：[1]武汉大学人民医院肿瘤科,430060

出　　处：《医药导报》2011年第9期1160-1162,共3页Herald of Medicine

摘　　要：目的观察紫杉醇脂质体联合奈达铂治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒副作用。方法 17例晚期NSCLC患者采用紫杉醇脂质体135 mg.(m2)-1,静脉滴注3 h,第1天;联合奈达铂80 mg.(m2)-1,静脉滴注,第2天2,1 d为1个周期,化疗2～6个周期。结果 17例患者均可评价近期疗效:完全缓解1例,部分缓解4例,稳定3例,进展9例。毒副作用主要为血液学毒副作用,以白细胞和血小板减少为主;非血液学毒副作用中恶心呕吐、肝功能轻度损伤、脱发例数较多。结论紫杉醇脂质体联合奈达铂方案治疗晚期非小细胞肺癌疗效较好,毒副作用可以耐受。Objective To evaluate the efficacy and toxicity of paclitaxel liposome plus nedaplatin in the treatment of advanced non-small cell lung cancer（NSCLC）. Methods 17 cases of NSCLC treated with paclitaxel liposome and nedaplatin for 2 to 6 cyeles, by infusing paclitaxel liposome 135 mg·（m^2）^-1 for 3 h on day 1 and combining nedaplatin 80 mg·（m^2）^-1 as infusion on day 2. Results Among 17 patients being evaluated for response to treatment, 1 showed complete response（CR） , 4 showed partial response （PR） , 3 showed stable disease （SD） , 9 showed progress disease （PD）. The main side reaction was haematological toxicity, including neutropenia and thromboeytopenia. The non-haemutological toxicity was nausea and wnniting, mild liver injury, and fair loss. Conclusion Paclitaxel liposome plus nedaplatin was effective and well tolerated lot treating patients with advanced non-small cell lung cancer.

关 键 词：紫杉醇脂质体 奈达铂 癌 非小细胞肺 

分 类 号：R286[医药卫生—中药学] R692[医药卫生—中医学]